Until now, few studies have looked at the effects of anti-obesity drugs on HIV-positive people, who are nevertheless affected by abnormal fat accumulation. Explanations on this potential drug which could control the metabolic problems of people affected by HIV.
Semaglutide – marketed as Wegovy for obesity and Ozempic for diabetes – mimics a hormone called glucagon-like peptide 1, which helps control appetite and lower blood sugar levels. This medicine could also help people HIV positiveHIV positive, based on recent work presented this month at the Retroviruses and Opportunistic Infections Conference in Denver. “ If early data on the effects of the treatments are confirmed, these drugs could become essential for controlling the metabolic problems often caused by anti-inflammatory drugs.HIVHIV », Reports a press release published in Nature.
You should know that fatty liver (an accumulation of fats in the liverliver) affects 30 to 40% of HIV-positive people. Indeed, prolonged use of anti-HIV drugs can cause abnormal accumulation of fat, including in the area of theabdomenabdomen. As the disease progresses, it can cause liver failure and cardiovascular disease. There is also a risk ofinflammationinflammationeven well-controlled HIV can lead to a state of chronic inflammation.
The benefit of semaglutide
Researchers analyzed the results of the use of semaglutide, during a clinical testclinical test conducted in 222 people affected by HIV and steatotic liver disease coupled with metabolic dysfunction. The drug was associated with an average weight loss of 6.5 kilos in one year, or 5.7% of initial weight.
The trial consisted of a weekly injection of the moleculemolecule for approximately six months in patients receiving treatment for HIV. These preliminary results are promising for improving the health of HIV-positive people, with 29% of participants having benefited from resolutionresolution complete liver disease.
